Guide to Apolipoprotein B (ApoB)

WRITTEN BY
Updated: 05/22/2025|12 min read

Summary

ApoB carries cholesterol through the body and is a critical player in lipid metabolism and cardiovascular health. Elevated levels are associated with an increased cardiovascular disease risk and are considered a more sensitive marker than traditional cholesterol tests.

Why It Matters

Apolipoprotein B (ApoB) is arguably one of the most important markers for cardiovascular health, yet it remains underutilized in standard lipid testing. What makes ApoB particularly valuable is its unique ability to directly measure the number of potentially harmful lipoprotein particles in your bloodstream. Each atherogenic (artery-clogging) particle contains exactly one ApoB molecule, making it a more precise measurement of cardiovascular risk.

Traditional lipid panels focus on low-density lipoprotein (LDL) cholesterol, which can be misleading because it only measures the cholesterol content within LDL particles. The crucial factor in cardiovascular disease isn't just how much cholesterol is floating around, but rather how many particles can penetrate arterial walls and create plaque. Two people with identical LDL cholesterol levels can have significantly different numbers of particles and, therefore, very different actual risks of heart disease.

Free lab interpretation

Already have labs?

Get a free interpretation grounded in Levels biomarker expertise and informed by our dataset of over 1.5 billion health data points.

Upload your labs free

ApoB can indicate cardiovascular risk even when other lipid markers appear normal, in part because it captures all potentially dangerous particles: not just LDL, but also very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and lipoprotein(a). This comprehensive measurement helps identify hidden cardiovascular risk in people with metabolic conditions like diabetes or obesity, where traditional lipid panels often fail to capture the whole picture.

Research has consistently shown that ApoB is more strongly associated with cardiovascular events than LDL cholesterol, non-HDL cholesterol, or other traditional lipid markers. This is particularly true when there's a discordance between different cholesterol measurements or in people with metabolic syndrome, where particle numbers may be elevated even when cholesterol levels appear normal.

The good news is that ApoB levels can be modified through both lifestyle changes and medical interventions when necessary.

Associated Symptoms

ApoB levels themselves are laboratory findings rather than medical conditions. However, elevated levels may be associated with cardiovascular conditions that can eventually cause symptoms. It's important to note that high ApoB often has no symptoms in its early stages, which makes testing particularly valuable for early detection.

Common symptoms that may indicate advanced cardiovascular conditions associated with prolonged high ApoB:

  • Chest pain or discomfort (angina): May occur during physical activity or stress when narrowed arteries can't deliver enough oxygen to the heart
  • Shortness of breath: Can develop when heart function is compromised due to coronary artery disease
  • Fatigue with exertion: May result from reduced oxygen delivery to muscles and tissues
  • Heart palpitations or irregular heartbeat: Can occur when plaque in arteries affects the heart's electrical system
  • Leg pain or cramping when walking (claudication): Caused by reduced blood flow to lower extremities due to peripheral artery disease
  • Swelling in ankles or feet: May develop with advanced heart failure resulting from long-term coronary artery disease

Less common symptoms that may occur with severe cardiovascular disease:

  • Jaw, neck, or back pain: Alternative presentations of heart-related pain, especially in women
  • Nausea or cold sweats: Can accompany acute cardiac events
  • Dizziness or lightheadedness: May result from compromised blood flow to the brain

Signs that may be observed in physical examination:

  • Xanthomas: Yellowish cholesterol deposits under the skin, particularly around tendons or joints, seen in some genetic lipid disorders
  • Corneal arcus: White/gray ring around the cornea, when appearing before age 50 may indicate familial hypercholesterolemia
  • Yellowish deposits around the eyelids (xanthelasma): May indicate chronic elevation of lipids

It's important to emphasize that cardiovascular disease associated with high ApoB often develops silently over decades before causing symptoms. By the time symptoms appear, significant arterial damage may have already occurred. This is why ApoB testing and other preventative measures are valuable for detecting risk long before symptoms develop.

Clinical Ranges

Lab Reference Range: <90 mg/dL

Lifestyle Factors That Can Impact It

Factors that can improve ApoB levels:

  • Adopting a healthy, balanced, and nutritious diet diet rich in olive oil, fish, and vegetables
  • Reduce sugar intake
  • Include fermented dairy products
  • Regular aerobic exercise (at least 150 minutes per week)
  • Maintaining a healthy weight
  • Reducing intake of refined carbohydrates (i.e., sugar, wheat flour) and processed foods
  • Increasing fiber consumption, especially soluble fiber
  • Getting adequate sleep (7-9 hours per night)
  • Stress management practices

Factors that could lead to worse ApoB levels:

  • High intake of trans fats and processed foods
  • Excessive alcohol consumption
  • Sedentary lifestyle
  • Smoking
  • Poor sleep habits
  • Chronic stress
  • High sugar intake

Other Factors That Can Impact It

Genetic Factors

  • Familial hypercholesterolemia (FH): An inherited condition that causes extremely high ApoB levels from birth due to impaired LDL receptor function. FH can increase heart disease risk by 10-20 times if untreated.
  • ApoE gene variants: Different versions of this gene can affect how efficiently your body processes and clears lipoproteins. The ApoE4 variant, in particular, is associated with higher ApoB levels.
  • PCSK9 gene mutations: Some mutations can increase PCSK9 protein activity, leading to fewer LDL receptors and higher ApoB levels. Conversely, beneficial mutations can result in very low ApoB and strong protection against heart disease.
  • Other lipid metabolism genetic variants: Various genes involved in lipoprotein production, processing, and clearance can influence ApoB levels. These include LPL, APOB, and LDLR genes.

Medical Conditions

  • Hypothyroidism: Low thyroid function reduces LDL receptor activity and slows the clearance of ApoB-containing particles, leading to higher levels.
  • Pregnancy: Generally increases through pregnancy and gradually returns to patient baseline after delivery
  • Diabetes: Insulin resistance and high blood sugar can increase liver production of VLDL particles, each containing an ApoB molecule, resulting in higher total ApoB.
  • Metabolic syndrome: The combination of insulin resistance, inflammation, and altered fat metabolism typically increases ApoB particle production.
  • Chronic kidney disease: Impaired kidney function affects lipoprotein metabolism and can lead to the accumulation of ApoB-containing particles.
  • Certain inflammatory conditions: Chronic inflammation can alter lipid metabolism and increase ApoB particle production. Conditions like rheumatoid arthritis and lupus are often associated with higher ApoB levels.

Supplements and Medications

Medications:

  • Statins: The primary medical therapy for high ApoB, reducing liver production of lipoproteins and increasing their clearance, typically lowering ApoB by 30-50%.
  • PCSK9 inhibitors: Monoclonal antibodies that dramatically increase LDL receptor activity, potentially lowering ApoB by 50-60%.
  • Ezetimibe: Blocks cholesterol absorption in the intestine, working synergistically with statins to lower ApoB by an additional 15-20%.
  • Niacin: Can help reduce total cholesterol, LDL, Apo-B, Triglycerides.
  • Bempedoic acid: A newer medication that reduces liver production of cholesterol and ApoB-containing particles, particularly useful for statin-intolerant patients.

Supplements:

Note that supplements are not evaluated for efficacy or regulated by the FDA, and different brands may contain different amounts or concentrations of components. Look for brands that have been third-party tested, and always speak with your healthcare professional before beginning any supplement regime.

  • Red yeast rice: Contains natural compounds similar to statins that can lower ApoB production in the liver by 20-30%. Note that different supplements of Red Yeast Rice can have unpredictable concentrations of monacolin A (Lovastatin).
  • Fish oil (EPA/DHA): Reduces triglyceride synthesis in the liver, leading to fewer VLDL particles and lower ApoB levels.
  • Berberine: Increases LDL receptor expression and improves insulin sensitivity, potentially lowering ApoB by 10-15%.
  • Plant sterols: Compete with cholesterol for absorption in the intestine, potentially reducing ApoB levels by 5-10%.
  • Citrus bergamot: Contains unique flavonoids that can improve lipid metabolism

How it Relates to Other Markers

Understanding how ApoB relates to other cholesterol markers can provide crucial insights into cardiovascular risk:

  • Low ApoB with High LDL-C: This suggests you have a smaller number of cholesterol-rich LDL particles. Generally, this pattern carries less cardiovascular risk than having a high number of particles. This pattern is relatively uncommon but can occur in some genetic variations.
  • High ApoB with Normal/Low LDL-C: This indicates a large number of cholesterol-depleted particles, often seen in metabolic syndrome, insulin resistance, and diabetes. This pattern can be particularly dangerous because traditional lipid panels might suggest low risk while significant cardiovascular risk exists.
  • High ApoB with High LDL-C: This represents the highest risk pattern, indicating a large number of particles and high cholesterol content. This pattern often requires aggressive intervention.
  • Low ApoB with Low LDL-C: This is the optimal pattern, indicating a low number of particles and low cholesterol content.

What Borderline Values (90-100 mg/dL) Could Mean in Relation to Other Markers

  • With normal LDL: May indicate small, dense LDL particles; consider additional testing
  • With high LDL: Suggests typical pattern; focus on standard lipid-lowering approaches
  • With high triglycerides: May indicate metabolic syndrome; focus on lifestyle interventions
  • In young adults: More concerning than in elderly
  • With family history: Consider more aggressive management
  • Trending up: More concerning than stable values
  • Post-treatment: May indicate need for therapy adjustment
  • With inflammation: May underestimate cardiovascular risk

Testing Accuracy and Stability

Factors That Can Affect the Accuracy of Your Test

  • Fasting Status: Unlike LDL cholesterol, ApoB is relatively stable regardless of fasting state. However, most labs still recommend a 9-12 hour fast for consistency with other lipid measurements.
  • Time of Day: ApoB shows minimal diurnal variation, making it reliable any time. This is an advantage over traditional lipid testing which can vary up to 10% throughout the day.
  • Recent Illness: Acute infections or inflammatory conditions can temporarily affect ApoB levels, typically causing a modest decrease. Wait at least 2-3 weeks after recovery for testing.
  • Recent Exercise: Intense exercise within 24 hours before testing can temporarily lower ApoB levels by 5-10%.

Biological Variability

  • Day-to-Day Stability: ApoB is one of the more stable lipid markers, with day-to-day variability typically less than 5-6% in healthy people.
  • Week-to-Week Changes: In the absence of interventions, ApoB levels usually vary by less than 10% over several weeks.

When Results May Be Less Reliable

  • Recent significant weight change (>5% of body weight in a month)
  • Acute liver disease or dysfunction
  • Severe illness or major surgery within the past month
  • Pregnancy or recent childbirth (within 6 weeks)
  • Certain medications, particularly if recently started or stopped

Follow-Up Considerations

When Re-Testing May be Appropriate

  • Regular ApoB testing every 3-6 months when implementing interventions
  • Annual testing for stable levels
  • More frequent monitoring for those with genetic conditions
  • Regular assessment of cardiovascular risk factors
  • Adjustment of treatment plans based on response

Additional Testing Your Doctor May Consider

  • Advanced lipoprotein testing (NMR LipoProfile)
  • Genetic testing for FH if ApoB is significantly elevated
  • Cardiovascular calcium scoring
  • CIMT (Carotid intima-media thickness) testing
  • Assessment of other cardiovascular risk markers

When Additional Care May be Warranted

  • ApoB levels persistently above 100 mg/dL despite lifestyle changes
  • Family history of early cardiovascular disease
  • Presence of other cardiovascular risk factors
  • Symptoms of cardiovascular disease
  • Genetic risk factors identified

Further Reading

Why ApoB may be a better cholesterol marker

Bibliography

References

1. Borén, Jan, et al. "Low-Density Lipoproteins Cause Atherosclerotic Cardiovascular Disease: Pathophysiological, Genetic, and Therapeutic Insights: A Consensus Statement from the European Atherosclerosis Society Consensus Panel." European Heart Journal, vol. 41, no. 24, 2020, pp. 2313-2330. Oxford Academic, https://doi.org/10.1093/eurheartj/ehz962.

2. Emerging Risk Factors Collaboration. "Major Lipids, Apolipoproteins, and Risk of Vascular Disease." JAMA, vol. 302, no. 18, 2009, pp. 1993-2000. American Medical Association, https://doi.org/10.1001/jama.2009.1619.

3. Grundy, Scott M., et al. "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol." Journal of the American College of Cardiology, vol. 73, no. 24, 2019, pp. e285-e350. Elsevier, https://doi.org/10.1016/j.jacc.2018.11.003.

4. Langlois, Michel R., et al. "Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations." Clinical Chemistry, vol. 64, 2018, pp. 1006-1033. American Association for Clinical Chemistry, https://doi.org/10.1373/clinchem.2018.287074.

5. Richardson, Thomas G., et al. "Evaluating the Relationship Between Circulating Lipoprotein Lipids and Apolipoproteins with Risk of Coronary Heart Disease: A Multivariable Mendelian Randomization Analysis." PLOS Medicine, vol. 17, no. 3, 2020, e1003062. Public Library of Science, https://doi.org/10.1371/journal.pmed.1003062.

6. Sniderman, Allan D., et al. "A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk." Circulation: Cardiovascular Quality and Outcomes, vol. 4, 2011, pp. 337-345. American Heart Association, https://doi.org/10.1161/CIRCOUTCOMES.110.959247.

7. Sniderman, Allan D., et al. "Discordance Analysis of Apolipoprotein B and Non-High-Density Lipoprotein Cholesterol as Markers of Cardiovascular Risk in the INTERHEART Study." Atherosclerosis, vol. 225, 2012, pp. 444-449. Elsevier, https://doi.org/10.1016/j.atherosclerosis.2012.08.002.

8. Walldius, G., and I. Jungner. "The ApoB/ApoA‐I Ratio: A Strong, New Risk Factor for Cardiovascular Disease and a Target for Lipid‐Lowering Therapy – A Review of the Evidence." Journal of Internal Medicine, vol. 259, no. 5, 2006, pp. 493-519. Wiley Online Library, https://doi.org/10.1111/j.1365-2796.2006.01643.x.

9. Welsh, Claire, et al. "Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease." Circulation, vol. 140, 2019, pp. 542-552. American Heart Association, https://doi.org/10.1161/CIRCULATIONAHA.119.041149.

10. Willeit, Peter, et al. "Baseline and On-Statin Treatment Lipoprotein(a) Levels for Prediction of Cardiovascular Events: Individual Patient-Data Meta-Analysis of Statin Outcome Trials." The Lancet, vol. 392, 2018, pp. 1311-1320. Elsevier, https://doi.org/10.1016/S0140-6736(18)31652-0.

LEVELS APP + LABS

See how the Levels Heart Health program can help improve your ApoB.

  • Follow app-guided targets for fiber, saturated fat, and net carbs
  • Levels Heart Health cohorts have observed up to a 30% reduction in ApoB
  • Retest ApoB to measure progress
Take the 60-second plan quiz

Get a free interpretation grounded in Levels biomarker expertise and informed by our dataset of over 1.5 billion health data points.

Upload your labs free
LEVELSAI

Ask a question about this topic

Get instant answers to your health and nutrition questions with an AI Search powered by the full Levels blog.

Try LevelsAI
Sign up for the Levels Newsletter